All FDA drug approvals

FDA approval · Drugs@FDA

HEPARIN SODIUMheparin sodium

NDA000552 ·

FDA approved the original new drug application for HEPARIN SODIUM on February 9, 1939, sponsored by ASPEN GLOBAL INC. FDA marks all 12 products under the application discontinued. FDA has approved 1 efficacy supplement on the application since, the most recent on April 11, 1986.

Application
NDA000552
Sponsor
ASPEN GLOBAL INC
Original approval
Active ingredient
heparin sodium

Products under this application

Ingredient and strengthFormRouteMarketing status
heparin sodium 1,000 UNITS/MLINJECTABLEINJECTIONDiscontinued
heparin sodium 5,000 UNITS/MLINJECTABLEINJECTIONDiscontinued
heparin sodium 1,000 UNITS/MLINJECTABLEINJECTIONDiscontinued
heparin sodium 10,000 UNITS/MLINJECTABLEINJECTIONDiscontinued
heparin sodium 40,000 UNITS/MLINJECTABLEINJECTIONDiscontinued
heparin sodium 5,000 UNITS/MLINJECTABLEINJECTIONDiscontinued
heparin sodium 100 UNITS/MLINJECTABLEINJECTIONDiscontinued
heparin sodium 10,000 UNITS/MLINJECTABLEINJECTIONDiscontinued
heparin sodium 10,000 UNITS/MLINJECTABLEINJECTIONDiscontinued
heparin sodium 1,000 UNITS/MLINJECTABLEINJECTIONDiscontinued
heparin sodium 5,000 UNITS/MLINJECTABLEINJECTIONDiscontinued
heparin sodium 20,000 UNITS/MLINJECTABLEINJECTIONDiscontinued

What “discontinued” means in FDA’s record

Drugs@FDA marks a product discontinued when it was never marketed, when it has been taken off the market, when it is made only for export, when it is made for military use, or when its approval was withdrawn for a reason other than safety or effectiveness. The record does not say which of those applies to a given product. The word on its own is not evidence that FDA found the drug unsafe.

Source: FDA, Drugs@FDA glossary of terms, under “Discontinued Drug Product”.

Approved efficacy supplements

An efficacy supplement is how a sponsor asks FDA to approve a change that needs clinical evidence — most often a new indication. FDA’s record gives each one a submission number, a date and a review priority. It does not say what any supplement approved, so neither does this page. The approval letter and label for each are on accessdata.fda.gov under the application number.

ApprovedSupplementReview
S-18

FDA records other approved supplements on this application, by the class code it assigns them: Manufacturing (CMC) 8 · Labeling 5 · REMS 2. Those are changes to the label or to how the drug is made rather than new clinical evidence, so they are counted here and not listed.

Source: FDA’s Drugs@FDA application file, via openFDA (export 2026-09-03). Every field on this page comes from that record.

An approval date is the start of the question, not the end

What a drug is worth to the company that owns it depends on what else is in the pipeline, how much cash is behind it and who else is running the same trial. FuzeBio reads a biotech end to end on demand — pipeline in plain English, trial design and endpoints, competitors, the cash position, and a valuation with its assumptions on the page. Moderna’s report is open in full, no account.

Open the Moderna report

A complete sample report — nothing held back, no sign-up.